A 37 year old male patient was diagnosed with sarcoidosis of lung and was kept on glucocoicoid therapy. The treatment may result in the bone loss because glucocoicoids causes which of the following?
First, the core concept here is glucocorticoid-induced osteoporosis. Glucocorticoids are known to have several adverse effects on bone density. They interfere with bone formation and increase bone resorption. So, the main idea is understanding the mechanisms by which these steroids lead to bone loss.
Now, the correct answer should relate to the inhibition of osteoblast activity. Osteoblasts are the cells responsible for bone formation. If glucocorticoids inhibit them, bone formation decreases. Also, they might increase the activity of osteoclasts, which break down bone. Another angle is the suppression of calcium absorption in the gut, leading to lower calcium levels, which can trigger increased parathyroid hormone (PTH) release, further stimulating bone resorption.
Looking at the options, even though they aren't listed here, the possible distractors might include things like increased bone formation, decreased calcium excretion, or other unrelated effects. For example, an option suggesting that glucocorticoids increase osteoblast activity would be incorrect. Another might claim they decrease osteoclast activity, which is also wrong because they actually promote resorption.
Clinical pearl: Remember that long-term corticosteroid use is a major risk factor for osteoporosis. Patients on such therapy should have their bone density monitored and may require calcium and vitamin D supplementation, or even bisphosphonates to prevent fractures.
Putting this all together, the correct answer is likely related to inhibiting osteoblast function or increasing osteoclast activity. The key is to explain the suppression of osteoblasts and the resulting decrease in bone formation, along with increased resorption.
**Core Concept**
Glucocorticoids induce bone loss via suppression of osteoblast function and increased osteoclast-mediated bone resorption. This is a key mechanism in glucocorticoid-induced osteoporosis, a major adverse effect of chronic steroid therapy.
**Why the Correct Answer is Right**
Glucocorticoids inhibit osteoblast differentiation and activity, reducing collagen synthesis and bone matrix production. They also enhance osteoclast activity by increasing receptor activator of nuclear factor kappa-B ligand (RANKL) expression, promoting bone resorption. Additionally, they decrease intestinal calcium absorption and suppress sex hormone production, further accelerating bone loss.
**Why Each Wrong Option is Incorrect**
**Option A:** *Increased osteoblast activity*—Incorrect. Glucocorticoids inhibit osteoblasts, not stimulate them.
**Option B:** *Decreased osteoclast activity*—Incorrect. Glucocorticoids increase osteoclast activity through RANKL upregulation.
**Option C:** *Increased intestinal calcium absorption*—Incorrect. Glucocorticoids reduce calcium absorption, contributing to hypocalcemia.
**Clinical Pearl / High-Yield Fact**
Never forget: Long-term glucocorticoid use is a *primary risk factor* for secondary osteoporosis. Prescribe calcium, vitamin D, and bisphosphonates to mitigate risk. Mnemonic: **“Steroids = Stress on Bones”** (Suppress bone formation, Stress resorption).